These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29851225)

  • 1. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.
    Marco A; Roget M; Cervantes M; Forné M; Planella R; Miquel M; Ortiz J; Navarro M; Gallego C; Vergara M;
    J Viral Hepat; 2018 Nov; 25(11):1280-1286. PubMed ID: 29851225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
    Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
    BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
    Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
    Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV infected prisoners: should they be still considered a difficult to treat population?
    Iacomi F; Iannicelli G; Franceschini A; Migliorisi P; Rosati S; Piselli P; Scognamiglio P; De Carli G; Marcellini S; Palmieri F
    BMC Infect Dis; 2013 Aug; 13():374. PubMed ID: 23945309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
    Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
    World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C].
    Juanbeltz R; Zozaya JM; Repáraz J; Castilla J; Sarobe MT; Úriz Otano JI; Gracia Ruiz de Alda M; San Miguel R
    An Sist Sanit Navar; 2017 Apr; 40(1):57-66. PubMed ID: 28534541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
    Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
    Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C in Canadian prison inmates.
    Farley JD; Wong VK; Chung HV; Lim E; Walters G; Farley TA; Yoshida EM
    Can J Gastroenterol; 2005 Mar; 19(3):153-6. PubMed ID: 15776135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of hepatitis C virus in a prison: An 18-year experience.
    Nogales-Garcia M; Parraza Diez N; Vargas Axpe A; Velasco Garcia R; Larrabeiti-Etxebarria A; Roy Lopez-Cano I; Atrio Alvarez I; Lopez de Arcaute Trincado A; Fernandez Lopez de Vicuña EM; Saez de Adana Arroniz E; Martínez Martínez C; Portu Zapirain J
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; 42(5):236-241. PubMed ID: 37117143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
    Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
    Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
    Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
    J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha MA; Harding D; Ralton L; Colman A; Liew D; Iyngkaran G; Tse E;
    J Viral Hepat; 2018 Nov; 25(11):1287-1297. PubMed ID: 29888827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
    Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
    Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
    Vanegas NO; Román JL; Febles MH; Sánchez CG; Suárez JM; Martínez ER; Hernández LO; López MJ
    Rev Esp Quimioter; 2011 Dec; 24(4):198-203. PubMed ID: 22173189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.